Report error Found 175 Enz. Inhib. hit(s) with all data for entry = 125
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Arrien Pharmaceuticals
US Patent
Arrien Pharmaceuticals
US Patent
Affinity DataIC50: <500nMpH: 7.5Assay Description:The 2×DYRK1A/Ser/Thr 18 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consi...More data for this Ligand-Target Pair
Affinity DataIC50: >500nMAssay Description:Procedure: Enzyme was incubated with substrate peptide in reaction buffer in the presence and absence of test compounds or Staurosporine. All additio...More data for this Ligand-Target Pair